Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition

Oncogene

Volumn 29, Issue 50, 2010, Pages 6557-6568

  Ji, C ^a   Yang, B ^b   Yang, Y L ^a   He, S H ^a   Miao, D S ^a   He, L ^c   Bi, Z G ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

AMPK; C6 ceramide; cancer chemotherapy; Doxorubicin; mTORC1 and apoptosis

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; C6 CERAMIDE; CERAMIDE DERIVATIVE; DOXORUBICIN; ETOPOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CERAMIDES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEINS; REACTIVE OXYGEN SPECIES; RIBONUCLEOTIDES;

EID: 78650303774     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.379     Document Type: Article

References (34)

1. Arad M, Seidman CE, Seidman JG. (2007). AMP-activated protein kinase in the heart: role during health and disease. Circ Res 100: 474-488.
2. Auzenne E, Leroux ME, Hu M, Pollock RE, Feig B, Klostergaard J. (1998). Cytotoxic effects of sphingolipids as single or multi-modality agents on human melanoma and soft tissue sarcoma in vitro. Melanoma Res 8: 227-239.
3. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. (1995). Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405-414.
4. Cao C, Lu S, Kivlin R, Wallin B, Card E, Bagdasarian A et al. (2008). AMP-activated protein kinase contributes to UV- and H2O2-induced apoptosis in human skin keratinocytes. J Biol Chem 283: 28897-28908.
5. Carling D. (2004). The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29: 18-24. (Pubitemid 38068476)
6. Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT et al. (2010). Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol 79: 162-171.
7. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. (2002). Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141-6145.
8. Hortobagyi GN. (1997). Anthracyclines in the treatment of cancer. An overview. Drugs 54(Suppl 4): 1-7.
9. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X et al. (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
10. Inoki K, Zhu T, Guan KL. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
11. 0-AMP-activated protein kinase. Am J Physiol Heart Circ Physiol 291: H1883-H1892.
12. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293.
13. Jung SN, Yang WK, Kim J, Kim HS, Kim EJ, Yun H et al. (2008). Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 29: 713-721.
14. Kahn BB, Alquier T, Carling D, Hardie DG. (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25.
15. Kim do Y, Park MW, Yuan HD, Lee HJ, Kim SH, Chung SH. (2009). Compound K induces apoptosis via CAMK-IV/AMPK pathways in HT-29 colon cancer cells. J Agric Food Chem 57: 10573-10578.
16. Kolesnick RN, Kronke M. (1998). Regulation of ceramide production and apoptosis. Annu Rev Physiol 60: 643-665.
17. Mehta S, Blackinton D, Omar I, Kouttab N, Myrick D, Klostergaard J et al. (2000). Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 46: 85-92.
18. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. (2006). Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66: 10100-10111.
19. NithipongVanitch R, Ittarat W, Cole MP, Tangpong J, Clair DK, Oberley TD. (2007). Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)? Antioxid Redox Signal 9: 1001-1008.
20. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S et al. (2007). Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283: 3979-3987.
21. Piguet AC, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C et al. (2008). Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 49: 78-87.
22. Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S et al. (2006). Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cel. Oncol Rep 16: 907-913.
23. Radin NS. (2003). Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J 371: 243-256.
24. Rath G, Schneider C, Langlois B, Sartelet H, Morjani H, Btaouri HE et al. (2009). De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. Int J Biochem Cell Biol 41: 1165-1172.
25. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G et al. (1999). 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59: 862-867.
26. Romano MF, Avellino R, Petrella A, Bisogni R, Romano S, Venuta S. (2004). Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 40: 2829-2836.
27. Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X et al. (2006). Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55(Suppl 2): S48-S54.
28. Steinberg GR, Kemp BE. (2009). AMPK in health and disease. Physiol Rev 89: 1025-1078.
29. Towler MC, Hardie DG. (2007). AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100: 328-341.
30. 0-monophosphate-activated protein kinase via intracellular calcium mobilization and activation of calcium/calmodulin-dependent protein kinase kinase-beta. Mol Endocrinol 22: 893-903.
31. Yoon H, Oh YT, Lee JY, Choi JH, Lee JH, Baik HH et al. (2008). Activation of AMP-activated protein kinase by kainic acid mediates brain-derived neurotrophic factor expression through a NF-kappaB dependent mechanism in C6 glioma cells. Biochem Biophys Res Commun 371: 495-500.
32. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. (2006). Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55: 2562-2570.
33. Zhang JF, Liu JJ, Lu MQ, Cai CJ, Yang Y, Li H et al. (2007). Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol 17: 162-168.
34. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA et al. (2009). Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119: 99-106.